C34.32 is a billable ICD-10 code used to specify a medical diagnosis of malignant neoplasm of lower lobe, left bronchus or lung. The code is valid during the fiscal year 2023 from October 01, 2022 through September 30, 2023 for the submission of HIPAA-covered transactions.
The following anatomical sites found in the Table of Neoplasms reference the parent code C34.3 of the current diagnosis code given the correct histological behavior: Neoplasm, neoplastic bronchus lower lobe of lung or Neoplasm, neoplastic lung lower lobe .
The code is linked to some Quality Measures as part of Medicare's Quality Payment Program (QPP). When this code is used as part of a patient's medical record the following Quality Measures might apply: Lung Cancer Reporting (biopsy/cytology Specimens) , Lung Cancer Reporting (resection Specimens).
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adenocarcinoma of left lung
- Malignant neoplasm of lower lobe bronchus
- Malignant neoplasm of lower lobe of left lung
- Neoplasm of bronchus of left lower lobe
- Primary adenocarcinoma of lower lobe of left lung
- Primary large cell carcinoma of lower lobe of left lung
- Primary malignant neoplasm of bronchus of left lower lobe
- Primary malignant neoplasm of lower lobe of left lung
- Primary non-small cell carcinoma of left lung
- Primary non-small cell carcinoma of lower lobe of left lung
- Primary small cell carcinoma of left lung
- Primary small cell carcinoma of lower lobe of left lung
- Primary squamous cell carcinoma of lower lobe of left lung
- Squamous cell carcinoma of bronchus
- Squamous cell carcinoma of bronchus in left lower lobe
- Squamous cell carcinoma of left lung
Convert to ICD-9 Code
|Source ICD-10 Code||Target ICD-9 Code|
|C34.32||162.5 - Mal neo lower lobe lung|
|Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.|
Quality Payment Program Measures
When code C34.32 is part of the patient's diagnoses the following Quality Measures apply and affect reimbursement. The objective of Medicare's Quality Measures is to improve patient care by making it more: effective, safe, efficient, patient-centered and equitable.
|Quality Measure||Description||Quality Domain||Measure Type||High Priority||Submission Methods|
|Lung Cancer Reporting (Biopsy/Cytology Specimens)||Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report.||Communication and Care Coordination||Process||YES||Claims, Registry|
|Lung Cancer Reporting (Resection Specimens)||Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type.||Communication and Care Coordination||Process||YES||Claims, Registry|
Table of Neoplasms
The parent code C34.3 of the current diagnosis code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
»lower lobe of lung
What is lung cancer?
Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
There are two main types: small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type.
Who is at risk for lung cancer?
Lung cancer can affect anyone, but there are certain factors that raise your risk of getting it:
- Smoking. This is the most important risk factor for lung cancer. Tobacco smoking causes about 9 out of 10 cases of lung cancer in men and about 8 out of 10 cases of lung cancer in women. The earlier in life you start smoking, the longer you smoke, and the more cigarettes you smoke per day, the greater your risk of lung cancer. The risk is also greater if you smoke a lot and drink alcohol every day or take beta carotene supplements. If you have quit smoking, your risk will be lower than if you had kept smoking. But you will still have a higher risk than people who never smoked.
- Secondhand smoke, which is the combination of smoke that comes from a cigarette and smoke breathed out by a smoker. When you inhale it, you are exposed to the same cancer-causing agents as smokers, although in smaller amounts.
- Family history of lung cancer
- Being exposed to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace
- Being exposed to radiation, such as from
- Radiation therapy to the breast or chest
- Radon in the home or workplace
- Certain imaging tests such as CT scans
- HIV infection
- Air pollution
What are the symptoms of lung cancer?
Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition.
If you do have symptoms, they may include:
- Chest pain or discomfort
- A cough that doesn't go away or gets worse over time
- Trouble breathing
- Blood in sputum (mucus coughed up from the lungs)
- Loss of appetite
- Weight loss for no known reason
- Trouble swallowing
- Swelling in the face and/or veins in the neck
How is lung cancer diagnosed?
Your health care provider may use many tools to make a diagnosis:
- A medical history, which includes asking about your symptoms
- A family history
- A physical exam
- Imaging tests, such as a chest x-ray or chest CT scan
- Lab tests, including tests of your blood and sputum
- A biopsy of the lung
If you do have lung cancer, your provider will do other tests to find out how far it has spread through the lungs, lymph nodes, and the rest of the body. This is called staging. Knowing the type and stage of lung cancer you have helps your provider decide what kind of treatment you need.
What are the treatments for lung cancer?
For most patients with lung cancer, current treatments do not cure the cancer.
Your treatment will depend on which type of lung cancer you have, how far it has spread, your overall health, and other factors. You may get more than one type of treatment.
The treatments for small cell lung cancer include:
- Radiation therapy
- Laser therapy, which uses a laser beam to kill cancer cells
- Endoscopic stent placement. An endoscope is a thin, tube-like instrument used to look at tissues inside the body. It may be used to put in a device called a stent. The stent helps to open an airway that has been blocked by abnormal tissue.
The treatments for non-small cell lung cancer include:
- Radiation therapy
- Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells
- Laser therapy
- Photodynamic therapy (PDT), which uses a medicine and a certain type of laser light to kill cancer cells
- Cryosurgery, which uses an instrument to freeze and destroy abnormal tissue
- Electrocautery, a treatment that uses a probe or needle heated by an electric current to destroy abnormal tissue
Can lung cancer be prevented?
Avoiding the risk factors may help to prevent lung cancer:
- Quitting smoking. If you don't smoke, don't start.
- Lower your exposure to hazardous substances at work
- Lower your exposure to radon. Radon tests can show whether your home has high levels of radon. You can buy a test kit yourself or hire a professional to do the test.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.
Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.
Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.
Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.
[Learn More in MedlinePlus]
Lung Cancer-Patient VersionLearn about lung cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]
Non-Small Cell Lung Cancer SummaryLearn about non-small cell lung cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)